Suppr超能文献

青光眼治疗方案的24小时疗效

24-h Efficacy of Glaucoma Treatment Options.

作者信息

Konstas Anastasios G P, Quaranta Luciano, Bozkurt Banu, Katsanos Andreas, Garcia-Feijoo Julian, Rossetti Luca, Shaarawy Tarek, Pfeiffer Norbert, Miglior Stefano

机构信息

1st University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

3rd University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

Adv Ther. 2016 Apr;33(4):481-517. doi: 10.1007/s12325-016-0302-0. Epub 2016 Feb 24.

Abstract

Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis.

摘要

目前青光眼的治疗方法包括通过药物、激光或手术将眼压降低到预定的目标眼压水平,该水平与视力丧失的稳定或延缓进展相适应。在已发表的文献中,常常假设眼压控制意味着随时间进行单次眼压测量。虽然对青光眼患者进行单次眼压测量随访快速且方便,但此类测量往往无法充分反映未经治疗时的眼压特征,也不能反映24小时周期内治疗后眼压控制的质量。由于青光眼是一种24小时疾病,眼压升高的损害作用是持续的,因此我们的目标是了解所有治疗方案在24小时内的疗效,这是合乎逻辑的。本文首先回顾了昼夜和24小时眼压监测的概念和价值。然后对关于药物、激光和手术治疗方案24小时疗效的现有证据进行批判性评估。在过去十年中,多项对照试验显著增进了我们对所有青光眼治疗方案24小时疗效的理解。然而,仍需要更多长期证据来更好地评估青光眼治疗的24小时疗效以及眼压特征对青光眼进展和视力预后的精确影响。

相似文献

1
24-h Efficacy of Glaucoma Treatment Options.
Adv Ther. 2016 Apr;33(4):481-517. doi: 10.1007/s12325-016-0302-0. Epub 2016 Feb 24.
2
Twenty-four hour efficacy of glaucoma medications.
Prog Brain Res. 2015;221:297-318. doi: 10.1016/bs.pbr.2015.06.010. Epub 2015 Sep 9.
3
Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment.
Adv Ther. 2018 Nov;35(11):1775-1804. doi: 10.1007/s12325-018-0812-z. Epub 2018 Oct 20.
4
Systematic Review of Current Devices for 24-h Intraocular Pressure Monitoring.
Adv Ther. 2016 Oct;33(10):1679-1690. doi: 10.1007/s12325-016-0388-4. Epub 2016 Aug 16.
5
Meeting an unmet need in glaucoma: continuous 24-h monitoring of intraocular pressure.
Expert Rev Med Devices. 2012 May;9(3):225-31. doi: 10.1586/erd.12.14.
6
Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma.
Surv Ophthalmol. 2020 Mar-Apr;65(2):171-186. doi: 10.1016/j.survophthal.2019.09.004. Epub 2019 Oct 16.
7
Continuous 24-hour intraocular pressure monitoring for glaucoma--time for a paradigm change.
Swiss Med Wkly. 2012 Mar 28;142:w13545. doi: 10.4414/smw.2012.13545. eCollection 2012.
8
Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.
Ophthalmology. 2007 Feb;114(2):205-9. doi: 10.1016/j.ophtha.2006.07.060. Epub 2006 Nov 13.
9
Evaluation and treatment of glaucoma 24hours a day. Where are we and where are we going?
Arch Soc Esp Oftalmol (Engl Ed). 2020 Jul;95(7):345-352. doi: 10.1016/j.oftal.2020.03.005. Epub 2020 Apr 25.
10
Effect of repeated applanation tonometry on the accuracy of intraocular pressure measurements.
Curr Eye Res. 2010 Jun;35(6):475-9. doi: 10.3109/02713681003678824.

引用本文的文献

1
The impact of intraocular pressure fluctuations on the progression of glaucoma and associated factors.
Adv Ophthalmol Pract Res. 2025 Mar 12;5(2):142-148. doi: 10.1016/j.aopr.2025.03.002. eCollection 2025 May-Jun.
2
Five-Year Outcomes of iStent inject Implantation With or Without Phacoemulsification in Eyes with Open-Angle Glaucoma.
Ophthalmol Ther. 2025 Jun;14(6):1219-1235. doi: 10.1007/s40123-025-01134-x. Epub 2025 Apr 7.
4
Effect of latanoprost on choroidal thickness in patients with newly diagnosed primary open-angle glaucoma.
North Clin Istanb. 2024 Jul 31;11(4):271-276. doi: 10.14744/nci.2024.87405. eCollection 2024.
6
Synthesis and Characterization of a Novel Peptide Targeting Human Tenon Fibroblast Cells To Modulate Fibrosis: An Integrated Empirical Approach.
ACS Pharmacol Transl Sci. 2022 Nov 16;5(12):1254-1266. doi: 10.1021/acsptsci.2c00148. eCollection 2022 Dec 9.
8
How to Measure Intraocular Pressure: An Updated Review of Various Tonometers.
J Clin Med. 2021 Aug 27;10(17):3860. doi: 10.3390/jcm10173860.
9
Awareness and knowledge about glaucoma among patients visiting the screening clinic in Jeddah Eye Hospital, Saudi Arabia.
Int J Ophthalmol. 2021 Jun 18;14(6):887-895. doi: 10.18240/ijo.2021.06.15. eCollection 2021.

本文引用的文献

5
Effects of prostaglandin analogues on aqueous humor outflow pathways.
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):102-9. doi: 10.1089/jop.2013.0179. Epub 2013 Dec 20.
8
The diurnal and nocturnal effect of travoprost with sofZia on intraocular pressure and ocular perfusion pressure.
Am J Ophthalmol. 2014 Jan;157(1):44-49.e1. doi: 10.1016/j.ajo.2013.09.001. Epub 2013 Oct 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验